Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma

Major histocompatibility complex (MHC) class I downregulation is the primary immune evasion mechanism associated with failure in anti-PD-1/PD-L1 blockade therapies for cancer. Here, we examined the role of MEK signaling pathway inhibition in head and neck squamous cell carcinoma (HNSCC) both in vitr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Kang, Seong-Ho, Keam, Bhumsuk, Ahn, Yong-Oon, Park, Ha-Ram, Kim, Miso, Kim, Tae Min, Kim, Dong-Wan, Heo, Dae Seog
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6287796/
https://ncbi.nlm.nih.gov/pubmed/30546955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1515057
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados